308 related articles for article (PubMed ID: 23248976)
1. Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry.
Lavoie P; Boutin M; Auray-Blais C
Anal Chem; 2013 Feb; 85(3):1743-52. PubMed ID: 23248976
[TBL] [Abstract][Full Text] [Related]
2. Urinary globotriaosylsphingosine-related biomarkers for Fabry disease targeted by metabolomics.
Auray-Blais C; Boutin M; Gagnon R; Dupont FO; Lavoie P; Clarke JT
Anal Chem; 2012 Mar; 84(6):2745-53. PubMed ID: 22309310
[TBL] [Abstract][Full Text] [Related]
3. Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb₃-related analogues in Fabry disease.
Boutin M; Auray-Blais C
Anal Chem; 2014 Apr; 86(7):3476-83. PubMed ID: 24634980
[TBL] [Abstract][Full Text] [Related]
4. Tandem mass spectrometry multiplex analysis of methylated and non-methylated urinary Gb3 isoforms in Fabry disease patients.
Abaoui M; Boutin M; Lavoie P; Auray-Blais C
Clin Chim Acta; 2016 Jan; 452():191-8. PubMed ID: 26593248
[TBL] [Abstract][Full Text] [Related]
5. Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry.
Auray-Blais C; Blais CM; Ramaswami U; Boutin M; Germain DP; Dyack S; Bodamer O; Pintos-Morell G; Clarke JT; Bichet DG; Warnock DG; Echevarria L; West ML; Lavoie P
Clin Chim Acta; 2015 Jan; 438():195-204. PubMed ID: 25149322
[TBL] [Abstract][Full Text] [Related]
6. How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?
Auray-Blais C; Ntwari A; Clarke JT; Warnock DG; Oliveira JP; Young SP; Millington DS; Bichet DG; Sirrs S; West ML; Casey R; Hwu WL; Keutzer JM; Zhang XK; Gagnon R
Clin Chim Acta; 2010 Dec; 411(23-24):1906-14. PubMed ID: 20716442
[TBL] [Abstract][Full Text] [Related]
7. A metabolomic study reveals novel plasma lyso-Gb3 analogs as Fabry disease biomarkers.
Dupont FO; Gagnon R; Boutin M; Auray-Blais C
Curr Med Chem; 2013; 20(2):280-8. PubMed ID: 23092136
[TBL] [Abstract][Full Text] [Related]
8. Fabry Disease Biomarkers: Analysis of Urinary Lyso-Gb3 and Seven Related Analogs Using Tandem Mass Spectrometry.
Lavoie P; Boutin M; Abaoui M; Auray-Blais C
Curr Protoc Hum Genet; 2016 Jul; 90():17.22.1-17.22.12. PubMed ID: 27367162
[TBL] [Abstract][Full Text] [Related]
9. LC-MS/MS analysis of plasma lyso-Gb3 in Fabry disease.
Boutin M; Gagnon R; Lavoie P; Auray-Blais C
Clin Chim Acta; 2012 Dec; 414():273-80. PubMed ID: 23041216
[TBL] [Abstract][Full Text] [Related]
10. Globotriaosylsphingosine (lyso-Gb
Effraimidis G; Feldt-Rasmussen U; Rasmussen ÅK; Lavoie P; Abaoui M; Boutin M; Auray-Blais C
J Med Genet; 2021 Oct; 58(10):692-700. PubMed ID: 32963035
[TBL] [Abstract][Full Text] [Related]
11. A metabolomic study to identify new globotriaosylceramide-related biomarkers in the plasma of Fabry disease patients.
Manwaring V; Boutin M; Auray-Blais C
Anal Chem; 2013 Oct; 85(19):9039-48. PubMed ID: 23968398
[TBL] [Abstract][Full Text] [Related]
12. The clinical utility of total concentration of urinary globotriaosylsphingosine plus its analogues in the diagnosis of Fabry disease.
Alharbi FJ; Baig S; Rambhatla SB; Vijapurapu R; Auray-Blais C; Boutin M; Steeds R; Wheeldon N; Dawson C; Geberhiwot T
Clin Chim Acta; 2020 Jan; 500():120-127. PubMed ID: 31654629
[TBL] [Abstract][Full Text] [Related]
13. Diurnal Variation of Urinary Fabry Disease Biomarkers during Enzyme Replacement Therapy Cycles.
Boutin M; Lavoie P; Menkovic I; Toupin A; Abaoui M; Elidrissi-Elawad M; Arthus MF; Fortier C; Ménard C; Maranda B; Bichet DG; Auray-Blais C
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32854306
[TBL] [Abstract][Full Text] [Related]
14. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
[TBL] [Abstract][Full Text] [Related]
15. Nano-LC-MS/MS for Quantification of Lyso-Gb3 and Its Analogues Reveals a Useful Biomarker for Fabry Disease.
Sueoka H; Ichihara J; Tsukimura T; Togawa T; Sakuraba H
PLoS One; 2015; 10(5):e0127048. PubMed ID: 25965380
[TBL] [Abstract][Full Text] [Related]
16. High-Risk Screening of Fabry Disease: Analysis of Fifteen Urinary Methylated and Non-Methylated Gb
Abaoui M; Boutin M; Lavoie P; Auray-Blais C
Curr Protoc Hum Genet; 2016 Oct; 91():17.24.1-17.24.11. PubMed ID: 27727434
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers associated with clinical manifestations in Fabry disease patients with a late-onset cardiac variant mutation.
Auray-Blais C; Lavoie P; Boutin M; Ntwari A; Hsu TR; Huang CK; Niu DM
Clin Chim Acta; 2017 Mar; 466():185-193. PubMed ID: 28108302
[TBL] [Abstract][Full Text] [Related]
18. Separation and Analysis of Lactosylceramide, Galabiosylceramide, and Globotriaosylceramide by LC-MS/MS in Urine of Fabry Disease Patients.
Boutin M; Menkovic I; Martineau T; Vaillancourt-Lavigueur V; Toupin A; Auray-Blais C
Anal Chem; 2017 Dec; 89(24):13382-13390. PubMed ID: 29099167
[TBL] [Abstract][Full Text] [Related]
19. A simple method for quantification of plasma globotriaosylsphingosine: Utility for Fabry disease.
Talbot A; Nicholls K; Fletcher JM; Fuller M
Mol Genet Metab; 2017 Sep; 122(1-2):121-125. PubMed ID: 28847675
[TBL] [Abstract][Full Text] [Related]
20. Globotriaosylsphingosine (Lyso-Gb
Alharbi FJ; Baig S; Auray-Blais C; Boutin M; Ward DG; Wheeldon N; Steed R; Dawson C; Hughes D; Geberhiwot T
J Inherit Metab Dis; 2018 Mar; 41(2):239-247. PubMed ID: 29294190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]